These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 9636628)
1. Superior efficacy of oral ganciclovir over oral acyclovir for cytomegalovirus prophylaxis in kidney-pancreas and pancreas alone recipients. Somerville T; Hurst G; Alloway R; Gaber A; Shokouh-Amiri MH; Stratta R Transplant Proc; 1998 Jun; 30(4):1546-8. PubMed ID: 9636628 [No Abstract] [Full Text] [Related]
2. Eradication of cytomegalovirus reactivation disease using high-dose acyclovir and targeted intravenous ganciclovir in kidney and kidney/pancreas transplantation. Shen GK; Alfrey EJ; Knoppel CL; Dafoe DC; Scandling JD Transplantation; 1997 Sep; 64(6):931-3. PubMed ID: 9326425 [TBL] [Abstract][Full Text] [Related]
3. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354 [TBL] [Abstract][Full Text] [Related]
4. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Flechner SM; Avery RK; Fisher R; Mastroianni BA; Papajcik DA; O'Malley KJ; Goormastic M; Goldfarb DA; Modlin CS; Novick AC Transplantation; 1998 Dec; 66(12):1682-8. PubMed ID: 9884259 [TBL] [Abstract][Full Text] [Related]
5. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021 [TBL] [Abstract][Full Text] [Related]
6. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation. Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408 [TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus disease prophylaxis in renal transplantation by high dose oral acyclovir: efficacy and limits. Bertoni E; Rosati A; Zanazzi M; Moscarelli L; Di Maria L; Piperno R; Orsi A; Parri F; Dedola G; Salvadori M Transplant Proc; 1998 Aug; 30(5):2094. PubMed ID: 9723402 [No Abstract] [Full Text] [Related]
8. Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation. Jung C; Engelmann E; Borner K; Offermann G Transplant Proc; 2001; 33(7-8):3621-3. PubMed ID: 11750538 [No Abstract] [Full Text] [Related]
9. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. Green M; Kaufmann M; Wilson J; Reyes J Clin Infect Dis; 1997 Dec; 25(6):1344-9. PubMed ID: 9431375 [TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus prophylaxis by ganciclovir followed by high-dose acyclovir in renal transplantation: a randomized, controlled trial. Pouteil-Noble C; Megas F; Chapuis F; Bosshard S; Colin C; Hadj-Aissa A; Pozet N; Martin X; Lefrançois N; Garnier JL; Aymard M; Touraine JL Transplant Proc; 1996 Oct; 28(5):2811. PubMed ID: 8908072 [No Abstract] [Full Text] [Related]
11. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients. Winston DJ; Busuttil RW Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129 [TBL] [Abstract][Full Text] [Related]
12. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy. Turgeon N; Fishman JA; Basgoz N; Tolkoff-Rubin NE; Doran M; Cosimi AB; Rubin RH Transplantation; 1998 Dec; 66(12):1780-6. PubMed ID: 9884276 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation. Speich R; Thurnheer R; Gaspert A; Weder W; Boehler A Transplantation; 1999 Jan; 67(2):315-20. PubMed ID: 10075601 [TBL] [Abstract][Full Text] [Related]
14. Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients. Reischig T; Opatrný K; Treska V; Mares J; Jindra P; Svecová M Kidney Blood Press Res; 2005; 28(4):218-25. PubMed ID: 16043964 [TBL] [Abstract][Full Text] [Related]
15. Ganciclovir/acyclovir prophylaxis reduces the incidence of cytomegalovirus infections in pancreas transplant recipients. Harland RC; Vernon WB; Bunzendahl H; Thompson JK; Lawrence C; Bollinger RR Transplant Proc; 1994 Apr; 26(2):432-3. PubMed ID: 8171488 [No Abstract] [Full Text] [Related]
16. Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants. Weng FL; Patel AM; Wanchoo R; Brahmbhatt Y; Ribeiro K; Uknis ME; Mulgaonkar S; Mathis AS Transplantation; 2007 Feb; 83(3):290-6. PubMed ID: 17297403 [TBL] [Abstract][Full Text] [Related]
17. Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation. Valenza M; Czer LS; Pan SH; Aleksic I; Freimark D; Harasty DA; Admon D; Barath P; Blanche C; Trento A J Heart Lung Transplant; 1995; 14(4):659-65. PubMed ID: 7578172 [TBL] [Abstract][Full Text] [Related]